Amanta Healthcare Limited · NSE:AMANTA
Amanta Healthcare — Q3 FY26 Earnings Presentation
38 slides from Amanta Healthcare's earnings presentation, Feb 11, 2026
Slide 1: Stock exchange intimation letter
Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: [email protected] Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 February 11, 2026 To, To, Sr. General Manager Sr. General Man
Slide 2: Q3 & 9M FY26 Investor Presentation
Amanta Healthcare Limited Q3 & 9M FY26 Investor Presentation February, 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Amanta Healthcare Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: 30+ Years of Sterile Liquids Legacy, A Niche Pharmaceutical Company
30+ Years of Sterile Liquids Legacy, A Niche Pharmaceutical Company Operational Metrics Financial Metrics A fully integrated Sterile Liquid manufacturer Revenue CAGR and marketer of Large Volume Parenterals 47 Product Portfolio (LVPs) and Small Volume Parenterals (SVPs) (FY21-25): 11.8% 1 Manufactur
Slide 5: Built to scale – Amanta’s differentiated business model
Built to scale – Amanta’s differentiated business model RM Sourcing Manufacturing Capabilities 3 Channel Distribution Key materials Sourced Manufacturing facility in Gujarat spanning 66,852 sq. mts Robust sales and distribution team with 18.5% strong presence across the globe LVP 4 lines SVP 3 lines
Slide 6: Company milestones
Company milestones 1994 1998 2002 2005 2007 2008 2014 2021 2024 2025 Added Launched De-bottle necking Commenced Successful launch Incorporated Implementation LVP Line - II Launched a Added SVP Line - II SteriPort and expansion of of IPO. Expansion and Converted of Large Volume (unlocking specialized
Slide 7: Solutions : A Diverse Product Portfolio (1/2)
Solutions : A Diverse Product Portfolio (1/2) Types of IV Fluids : Notable Formulations : Diluent Product Overview : Dextrose, Normal Saline, Combination Of Ciprofloxacin, Metronidazole, Ofloxacin, • Plain Water for Injection (WFI) Dextrose Normal Saline, Ringer Lactate, Paracetamol, Fluconazole. •
Slide 8: Solutions : A Diverse Product Portfolio (2/2)
Solutions : A Diverse Product Portfolio (2/2) Applications : Applications : Product Types : Administered through nebulisers for the treatment of Treatment for Infections, Glaucoma, lungs affected by Asthma or Bronchiectasis OTC Eye Lubricants Inflammation. Wound Cleaning Solutions Dosage Form : Dosa
Slide 9: Strategic Roadmap: Growth Levers
Strategic Roadmap: Growth Levers Action Plan for the next two years Complex dosages and niche molecules across anti-infectives, respiratory care, Wallet Share expansion and Ophthalmics. Scaling high-margin and SVP capacities by 5.39 crore and 10.78 Capacity Expansion crore units, with commissioning
Slide 10: Driving Success : Core Competitive Advantages
Driving Success : Core Competitive Advantages Well - established Pharma Manufacturer With Diverse Products & Markets Six therapeutic segments and container systems, 47 products registered in 120 countries. Wide Domestic And Global Marketing Network Pan-India network of 320 distributors, 96 sales sta
Slide 11: Differentiated Manufacturing technologies to market end product..
Differentiated Manufacturing technologies to market end product.. Injection Stretch-Blow Moulding (ISBM) Aseptic Blow Fill Seal (ABFS) The Sterilizer: Technology: • Technology: FFS (Form-Fill-Seal) is used • Sterilization Process: Fully automatic, • Technology: ISBM (Injection Stretch Blow for IV fl
Slide 12: (Part of LVP) – Our flagship product
(Part of LVP) – Our flagship product Currently operating at Installed • Launched the flagship brand in India in 2014 capacity of 6.62 Cr Bottles with 91% • is preferred by Oncologists, Pediatrician, Intensivist & Anaesthetist Utilization • First-mover advantage enabling better pricing discipline and
Slide 13: (LVP): New manufacturing Line to unlock Profitable Growth
(LVP): New manufacturing Line to unlock Profitable Growth SteriPort (LVP) Expansion in Capacity (In Cr.) Dedicated capacity within LVP, with 2 of 4 lines supporting Currently operating at 91% utilization, reflecting sustained demand visibility. 10.6 5 Cr bottles produced with negligible rejections,
Slide 14: SVP: High Margin Products - to move up the value chain
SVP: High Margin Products - to move up the value chain SVP Expansion in Capacity (Qty Cr.) Increasing share towards high margin 31.7 product – Accounting to 20% (INR 55Cr) of the revenue in FY25 • A 100% exports centric segment, Commissioned in 2005 and capacity tripled in 2008. 20.9 19.9% • Contrib
Slide 15: Excellent Manufacturing Facilities
Excellent Manufacturing Facilities Location: Certifications & Compliance: Production Capabilities: Block No: 872B, 873A, 874, 876 • ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO • Injections and 877 village Hariyala, District 45001:2018, WHO-GMP certified. • Oral Liquids Kheda Gujarat, India •
Slide 16: Sweating the assets to peak capacity
Sweating the assets to peak capacity Utilization % across each Parenteral Capex to drive future growth 130 91 73 83 99 89 94 91 97 93 25 FY23 FY24 FY25 12 10 6 LVP SVP Steriport Capex (INR Cr) FY25 Installed capacity (Units in crs) FY23 FY24 FY25 FY26P FY27P LVP (excluding SteriPort) 5.7 SVP 20.9 Ca
Slide 17: Increased Focus on exports – Driving higher margins
Increased Focus on exports – Driving higher margins 32% of revenue 68% of revenue Export markets 21 countries as of Fiscal 2025. Sales focus Domestic branded generics sold under proprietary brand names. Product range • LVP Pack Solutions: IV solutions, anti-fungal, and anti-protozoal formulations. •
Slide 18: De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 40% since FY23
De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 40% since FY23 • Aggressively reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs). • The equity denominator was significantly bolstered by a private plac
Slide 19: Setting up a Captive Solar power plant of 10.8 MW.
Setting up a Captive Solar power plant of 10.8 MW. 10.8 MW captive solar plant under implementation to structurally lower power costs Commissioning targeted in Q1 FY27, benefits to be reflected in FY27 and onwards. Total project cost: INR 34.8 Cr, largely debt-funded to preserve cash Low equity outl
Slide 20: Sector Analysis : Indian Domestic Formulation Market By Therapy & IV Fluids Overview
Sector Analysis : Indian Domestic Formulation Market By Therapy & IV Fluids Overview The Indian domestic formulation market is divided into chronic (53%) Key Therapy Areas In Domestic Formulation Market and acute (47%) segments in FY24. Therapy Share in Total Share in Total Share in Total CAGR CAGR
Slide 21: Export Excellence : The Indian Pharmaceutical Formulation Landscape
Export Excellence : The Indian Pharmaceutical Formulation Landscape Formulation exports grew by ~4.5% in FY23 after flat growth in FY22 due to Formulation Export Trend For India pricing pressure in the US market. India exported USD 12.3 bn worth of formulations to regulated markets in 23.5-24.0 FY24
Slide 22: The Board Of Directors
The Board Of Directors Mr. Bhavesh Patel Mr. Pratik Gandhi Mr. Nimesh Patel Chairman and Managing Director Non-Executive Director Non-Executive Director 30+ Years Of Experience 10+ Years Of Experience 3+ Years Of Experience Bhavesh Patel is the Chairman and Managing Pratik Gandhi is the Non-Executiv
Slide 23: The Board Of Directors
The Board Of Directors Ms. Anjali Choksi Mr. Kshitij Patel Mr. Nitin Jain Independent Director 15+ Independent Director 25+ Independent Director Years Of Experience Years Of Experience 20+ Years Of Experience Anjali Choksi is an Independent Director of Kshitij Patel is the Independent and Non- Nitin
Slide 24: Leadership Team
Leadership Team Paras Mehta - Chief Financial Officer : A qualified Chartered Accountant with over 20 years of experience working with Indian and multinational companies. Anil Rathi - Chief Operating Officer : A Graduate in Chemical Engineer & an MBA. He has over 25 years of experience in the pharma
Slide 25: Financial Performance – Q3 & 9M FY26
Financial Performance – Q3 & 9M FY26 (Figures in INR Cr.) Revenue EBITDA and Margins (%) PAT and Margins (%) 74 15 15 5 4 68 22% 21% 6% 6% Q3FY25 Q3FY26 Q3FY25 Q3FY26 Q3FY25 Q3FY26 Revenue EBITDA and Margins (%) PAT and Margins (%) 50 45 9 211 42 40 6 30 203 20 10 21% 21% 3% 4% 0 9MFY25 9MFY26 9MFY2
Slide 26: Strategic Highlights
Strategic Highlights Profitability increased by 51% in 9MFY26 on YoY basis Sustained revenue trajectory: Q3FY26 revenue stood at INR 75 cr, registering a 9.8% YoY growth, while 9MFY26 revenue reached INR 211 cr, marking a 3.97% YoY increase, reflecting steady demand and volume-led growth. Operationa
Slide 27: Revenue Breakdown – Annual performance
Revenue Breakdown – Annual performance (Figures in Rs. crs) Revenue from operations FY25 FY24 FY23 Revenue from contract with customers : Sale of products 267 272 253 Sale of services 5 6 5 Sub- total 272 278 258 Other operating revenue : Scrap sales 1 1 1 Export incentives 1 0 1 Total 275 280 259 2
Slide 28: Profit and Loss Statement
Profit and Loss Statement (Figures in Rs. crs) Particulars FY25 FY24 FY23 Revenues 275 280 259 Other Income 1 1 4 Total Income 276 282 263 Cost of materials consumed 101 86 101 Purchases of stock-in-trade 12 2 1 Changes in inventories of finished goods, work-in-process and stock-in-trade (20) 17 53
Slide 29: Balance Sheet
Balance Sheet (Figures in Rs. crs) Assets FY25 FY24 FY23 Equities & Liabilities FY25 FY24 FY23 Non-Current Assets Equity share capital 29 27 27 Property, plant and equipment 208 223 229 Other Equity 68 40 36 Capital work-in-progress 7 - - Net Worth 96 66 63 Right-of-use assets 9 5 9 Intangible asset
Slide 30: Annexure: Our Product Categories
Annexure Our Product Categories -
Slide 31: Fluid Therapy - (IV Fluid)
Fluid Therapy - (IV Fluid) Types of IV Fluids : • Dextrose • Normal Saline • Combination Of Dextrose Normal Saline • Ringer Lactate • Electrolytes Packaging Of Product : • Single Port container • Two Port container Fill Volume Options : • 100ml • 250ml • 500ml • 1000ml Innovative Technology : • Ster
Slide 32: Formulations
Formulations Product Focus : Fill Volume Range : • Injectables • 2ml to 100ml Therapeutic Products • Ophthalmic Segments • Respiratory Anti - fungal Fluconazole Technology : • Aseptic Blow-Fill- Seal (ABFS) & Notable Formulations: Injection Stretch Blow Moulding Anti – Pyretic Paracetamol (ISBM) tec
Slide 33: Diluents & Injectables
Diluents & Injectables Key Products : Pack Sizes : • Lidocaine • Offered in 5 ml & 10 ml • Potassium Chloride Products : • Magnesium Sulphate • Sterile Water for Injection (WFI) • Calcium Chloride • Normal Saline WFI • Calcium Gluconate Injectables Portfolio Diluents Overview 32
Slide 34: Ophthalmic
Ophthalmic Dosage Form : Therapeutic Product • 5ml & 10ml segments Ciprofloxacin Ophthalmic Solution U.S.P. (0.3 % Ophthalmic (FFS) w/v) Applications : Timolol Maleate Eye Drops B.P. (0.5 % w/v & Ophthalmic (FFS) • Including treatment for Infections, 0.25 % w/v) Applications: Packaging Options: Glau
Slide 35: Respiratory Solutions
Respiratory Solutions Dosage Form : • Available in 2.5ml Applications : • Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis. Key Product : • Budesonide Respiratory Suspension • Salbutamol Respiratory Solution • Salbutamol & Ipratropium Bromide Respirator
Slide 36: Irrigation Solutions
Irrigation Solutions Product Types : • OTC Eye Lubricants • Wound Cleaning Solutions Dosage Forms : • Available in 5ml, 10 ml & 20 ml Product : • Sodium Chloride Eye Wash • Wound Cleaning 35
Slide 37: Glossary
Glossary LVP: Large Volume Parenteral SVP: Small Volume Parenteral ABFS: Aseptic Blow Fill Seal ISBM: Injection Stretch-Blow Moulding WFI: Water For Injection SWFI: Sterile Water For Injection WHO-GMP: WHO Good Manufacturing Practices PICs: Pharmaceutical Inspection Co-operation Scheme ISO: Internat
Slide 38: Investor Relations contacts
Investor Relations Go India Advisors Amanta Healthcare Ltd. Name: Ms. Soumya Chhajed 8th Floor, Shaligram Corporates, Tel: +91-8619707750 C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India. Email:[email protected] Telephone: 079 6777 7600 Name: Ms. Shrutee Barve Email Id: [email protected] Te